Needham & Company LLC reiterated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research report released on Monday, December 23rd, AnalystRatings.com reports. The brokerage currently has a $84.00 price objective on the stock.
Other analysts have also issued reports about the company. Canaccord Genuity raised their target price on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a report on Wednesday, November 20th. TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a research report on Monday, October 28th. BidaskClub downgraded Crispr Therapeutics from a strong-buy rating to a buy rating in a research report on Friday, December 13th. Zacks Investment Research downgraded Crispr Therapeutics from a hold rating to a sell rating in a research report on Monday, September 30th. Finally, ValuEngine upgraded Crispr Therapeutics from a sell rating to a hold rating in a research report on Friday, November 1st. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $71.38.
Crispr Therapeutics stock traded up $0.69 during midday trading on Monday, hitting $59.68. 1,000,474 shares of the company were exchanged, compared to its average volume of 1,206,630. The firm has a market capitalization of $3.31 billion, a PE ratio of -17.35 and a beta of 3.20. Crispr Therapeutics has a fifty-two week low of $29.34 and a fifty-two week high of $74.00. The business has a fifty day simple moving average of $65.79 and a two-hundred day simple moving average of $51.88. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32.
Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, equities analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total transaction of $465,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. BSW Wealth Partners acquired a new position in Crispr Therapeutics during the 2nd quarter worth $39,000. Balyasny Asset Management LLC purchased a new stake in Crispr Therapeutics during the 2nd quarter worth about $5,165,000. Millennium Management LLC purchased a new stake in Crispr Therapeutics during the 3rd quarter worth about $4,366,000. BNP Paribas Arbitrage SA purchased a new stake in Crispr Therapeutics during the 2nd quarter worth about $41,000. Finally, Bank of New York Mellon Corp lifted its holdings in Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock worth $1,559,000 after buying an additional 17,810 shares during the last quarter. 49.82% of the stock is owned by institutional investors and hedge funds.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.